Rheumatology Biologics
“The Memory Palace”
The Analogy
This guide uses a memory palace — a technique where you walk through a familiar space and place what you need to remember in specific locations. Each room in the house maps to a drug class. Each fixture in the room maps to a specific drug or mechanism.
Start outside. There’s a garden hose spraying water onto the lawn. The water is cytokines. The grass is the receptor on the cell. Walk through the front door, into the living room, the kitchen, the B-cell death row, the garage, and out to the backyard. By the time you’re done, every biologic has a home.
To make it work really well, try walking through your own place (or a friend’s house, your childhood home, an open house) either physically (the best) or mentally. Try making the images absurd — the weirder, the more memorable.
Steps
The Garden Hose
“What Kind of Fix Is It?”
Three ways to stop the water: MABs soak up the stream, CEPTs catch the runoff, INIBs clog the hose from inside.
Start Learning →The Labeling System
“Read the Name, Know the Fix”
Every biologic has a name stamped on it by the WHO. The ending tells you how human it is.
Start Learning →Hidden Gems & the -KIN- Family
“Free Points in the Syllables”
HUMIRA spells out its mechanism. ABATE is in abatacept. Every drug with -KIN- in the name hunts an interleuKIN.
Start Learning →The House Tour
“Room by Room, Drug by Drug”
Front door (IL-1) → Thermostat (IL-6) → TV (IL-17) → Kitchen freezer (TNF) → B-Cell Death Row → Garage (JAK/TYK2) → Backyard (PDE4).
Start Learning →Step 1: The Garden Hose — “What Kind of Fix Is It?”
The grass is the receptor on the cell. Three ways to stop the water from hitting the grass:
-mab (Monoclonal AntiBodies) = Go straight for the source — soak up the stream before it hits the grass.
-cept (reCEPTor fusion proteins) = Hold a bucket between the nozzle and the grass — a decoy that catches the water before it reaches the real target.
-inib (small molecule INhIBitors) = Clog the hose from the inside — the flow stops, but you can’t see why from outside.
“MABs go straight for the source, CEPTs catch the runoff, INIBs clog the course.”
MABs find the target (cytokine or receptor) and bind directly to it — working outside the cell.CEPTs are decoy receptors that also work outside the cell, grabbing the cytokine before it reaches the real receptor.INIBs are tiny enough to get inside the cell and block signaling pathways (like JAK-STAT). The hose looks fine from the outside, but something’s clogged inside.
Step 2: The Labeling System — “Read the Name, Know the Fix”
Every biologic has a name stamped on it by the WHO. The ending before “-mab” tells you how human the antibody is. More mouse protein = more immunogenicity = more likely you’ll need methotrexate backup.
The Spectrum: Mouse → Human
| Substem | Origin | Mnemonic |
|---|---|---|
| -o-mab | Fully mouse | “O no, it’s all mOuse!” |
| -xi-mab | Chimeric (mixed) | “miXI-mab = a MIX of mouse and man” |
| -zu-mab | Humanized | “ZU-mab = almost human, just a ZU-spicion of mouse” |
| -u-mab | Fully human | “U-mab = it’s all hUman, it’s all U” |
“O is mOuse, X is miXed, ZU is humanized betwixt, U is hUman — least immunogenic in the mix.”
Why This Matters Clinically
Chimeric (-ximab): Most immunogenic → anti-drug antibodies form → loss of efficacy over time. This is WHY infliximab needs methotrexate as a co-pilot.
Fully human (-umab): Least immunogenic → can often be used as monotherapy.
Step 3: Name Cheat Codes — “Free Points Hiding in the Syllables”
Hidden Gems: Drug Names That Teach Themselves
| Drug | What’s Hiding | Mnemonic |
|---|---|---|
| HUMIRA | HUman Monoclonal antibody in Rheumatoid Arthritis | The brand name IS the mechanism + indication |
| Anakinra | Ana-KIN-RA = ANtagonist of interleuKIN Receptor Alpha/beta | The drug IS the body’s own IL-1Ra, cloned |
| Abatacept | “ABATE” = to reduce. It abates T-cell activation. | “ABATE the handshake — T cells won’t awake.” |
| Anifrolumab | “-fro-” = interFROn (WHO infix) | AN-ti-interFRO-n-lu-mab — the target is in the middle |
| Benlysta | B-lymphocyte stimulator antibody | “BenLYSTA — the B-LySt Antibody.” |
The “-KIN- Family” — Same Last Name, Different Targets
“See -KIN- in the name? It’s hunting an interleuKIN.”
| Drug | Target |
|---|---|
| Canakinumab | IL-1β |
| Ustekinumab | IL-12 + IL-23 |
| Secukinumab, Ixekizumab, Bimekizumab | IL-17 |
| Risankizumab, Guselkumab | IL-23 only |
Step 4: The House Tour — “Room by Room, Drug by Drug”
Now you have the tools and the cheat codes. Time to walk through the house. Each room maps to a drug class. For each drug, notice how the name confirms what you already know from Steps 1–3.
Pro tip — Make it YOUR house. Memory palaces work best when they’re personal. Walk through your own house and picture each drug class in a real room you know. The weirder the image, the stickier the memory.
🚨 The Front Door — IL-1 Inhibitors
IL-1 is the front door — the first signal that kicks off autoinflammatory fires (gout, FMF, CAPS, Still’s disease). These drugs guard the door.
“ANA blocks ALL IL-ONE at the door (alpha and beta). CANA? CAN only block beta, nothing more.”
Anakinra (Kineret)
Mechanism: IL-1 receptor antagonist (recombinant IL-1Ra). Blocks both alpha and beta.
Dosing: 100mg SC daily
FDA: RA, CAPS (NOMID). Also used for gout flares, Still’s disease, FMF, recurrent pericarditis.
Pearl: Injection site reactions common. Short half-life = quick washout if infection develops.
Canakinumab (Ilaris)
Mechanism: Monoclonal antibody against IL-1β specifically.
Dosing: 150mg SC every 8 weeks (varies by indication)
FDA: CAPS, SJIA, TRAPS, HIDS/MKD, FMF.
Pearl: CANTOS trial: reduced cardiovascular events — board-testable.
Rilonacept (Arcalyst)
Mechanism: Soluble decoy receptor (“IL-1 Trap”) — the -cept tells you it’s a decoy receptor. Catches both IL-1 alpha and beta.
Dosing: 320mg SC loading, then 160mg SC weekly
FDA: CAPS and recurrent pericarditis.
IL-1 Dosing: “ANA every DAY, RILO every WEEK, CANA every EIGHT — the IL-1 triple feat.”
🌡️ The Thermostat — IL-6 Inhibitors
IL-6 controls the thermostat — it drives fever and CRP. Block IL-6, and the thermostat reads normal. But the house is still burning. That’s the board trap. The smoke alarm (CRP) goes silent — but the fire (infection) is still raging.
“TOCI TOUCHES the SIX receptor — Giant Cell’s protector. SARI wraps SIX — same receptor, different fix.”
Tocilizumab (Actemra)
Mechanism: IL-6 receptor antibody. IV or SC.
Dosing: IV 4–8mg/kg every 4 weeks; SC 162mg weekly or every 2 weeks
FDA: RA, GCA, SJIA, PJIA, CRS (CAR-T), SSc-ILD.
Pearls: First-line for GCA (GiACTA trial). Monitor lipids. Risk of GI perforation. Masks infection signs — CRP stays low.
Sarilumab (Kevzara)
Mechanism: Also IL-6 receptor antibody. SC only.
Dosing: 200mg SC every 2 weeks
FDA: RA, PMR.
Pearl: Similar efficacy to tocilizumab, same monitoring. SC only (no IV option).
📺 The TV — IL-17 Inhibitors
IL-17 drives inflammation in the skin and spine. Think of it as an R-rated channel — you must be SEVENTEEN to watch.
“SECU-rity checks IDs at SEVENTEEN — but Crohn’s gets cancelled from the screen.”
Subtype pattern: Secukinumab and ixekizumab target IL-17A. Bimekizumab targets BOTH IL-17A AND IL-17F.
“BIME means BOTH — A and F, get out. Two subtypes, one drug, total knockout.”
Secukinumab (Cosentyx)
Dosing: 150–300mg SC; loading dose varies by indication, then every 4 weeks
FDA: Plaque psoriasis, PsA, AS, nr-axSpA, HS.
Pearl: Watch for Candida infections. Avoid in IBD (can worsen Crohn’s).
Ixekizumab (Taltz)
Dosing: 160mg SC loading, then 80mg SC every 2–4 weeks (varies by indication)
FDA: Plaque psoriasis, PsA, AS, nr-axSpA.
Pearl: Same IL-17A target as secukinumab. Also watch for Candida and IBD exacerbation.
Bimekizumab (Bimzelx)
Dosing: 320mg SC every 4 weeks initially, then every 4–8 weeks (varies by indication)
FDA: Plaque psoriasis, PsA.
Pearl: Dual IL-17A/F inhibition — the only IL-17 blocker that hits both subtypes. Higher rates of oral candidiasis. Avoid in IBD (class effect).
IL-12/23 and IL-23 Inhibitors
“USTE blocks the USUAL TWO — twelve AND twenty-three are through. GUSEL and RISAN are precise — only twenty-three, that’s their device.”
Ustekinumab (Stelara)
Mechanism: Monoclonal antibody against p40 subunit shared by IL-12 and IL-23.
Dosing: Weight-based IV loading dose, then 90mg SC every 8 or 12 weeks
FDA: Plaque psoriasis, PsA, Crohn’s, UC.
Pearl: Works for IBD! (Unlike IL-17 inhibitors). Excellent safety profile.
Guselkumab (Tremfya)
Mechanism: Monoclonal antibody against p19 (IL-23 selective).
Dosing: 100mg SC at weeks 0 and 4, then every 8 weeks
FDA: Plaque psoriasis, PsA.
Risankizumab (Skyrizi)
Mechanism: Monoclonal antibody against p19 (IL-23 selective).
Dosing: 150mg SC at weeks 0 and 4, then every 12 weeks (psoriasis); IV loading for Crohn’s
FDA: Plaque psoriasis, PsA, Crohn’s.
❄️ The Kitchen Freezer — TNF Inhibitors
TNF is the biggest source of flooding — the most water, the most damage. Five drugs stop it. Keep them on ICE in the freezer.
Adalimumab (Humira)
Mechanism: Fully human monoclonal antibody against TNF-alpha.
Name cheat: HUMIRA = HUman Monoclonal antibody in Rheumatoid Arthritis.
Dosing: 40mg SC every 2 weeks
FDA: RA, JIA, PsA, AS, plaque psoriasis, Crohn’s, UC, uveitis, HS.
Pearl: Most indications of any biologic. Now has biosimilars galore.
Infliximab (Remicade)
Mechanism: Chimeric monoclonal antibody. Given IV.
Mnemonic: “INFLIXI-mab — INFusion of a miXed-up creature.”
Dosing: 3–10mg/kg IV; induction at weeks 0, 2, 6, then every 4–8 weeks (varies by indication)
FDA: RA, Crohn’s, UC, AS, PsA, plaque psoriasis.
Pearls: Chimeric = higher immunogenicity → consider pairing with methotrexate. IV only. Check for latent TB before ALL TNF inhibitors. Can trigger drug-induced lupus.
Etanercept (Enbrel)
Mechanism: Soluble TNF receptor fusion protein (decoy receptor). The ONLY “-cept” among the TNF blockers.
Mnemonic: “The CEPT can CATCH but can’t CROHN’s — leave granulomas alone.”
Dosing: 50mg SC weekly
FDA: RA, JIA, PsA, AS, plaque psoriasis.
Pearl: Does NOT work for IBD, granulomatous diseases, or uveitis. Shorter half-life.
Certolizumab Pegol (Cimzia)
Mechanism: PEGylated Fab fragment — NO Fc portion. Cannot cross the placenta.
Mnemonic: “CERTolizumab is CERTified PEG-nant friendly.”
Dosing: 400mg SC at weeks 0, 2, 4, then 200mg every 2 weeks (or 400mg every 4 weeks)
FDA: RA, Crohn’s, PsA, AS, nr-axSpA, plaque psoriasis.
Pearl: Pregnancy safe — the only TNF inhibitor that does NOT cross the placenta. #1 tested fact.
Golimumab (Simponi)
Mechanism: Fully human monoclonal antibody. Monthly dosing.
Mnemonic: “GOLImumab — GO once a month, Live your life.”
Dosing: Simponi 50mg SC monthly; Simponi Aria 2mg/kg IV every 8 weeks
FDA: RA, PsA, AS, UC.
💀 B-Cell Death Row
B-cell death row, five ways to go. These drugs target B cells through depletion or starvation — each one a different way to eliminate rogue B cells driving autoimmunity.
“B-cell death row, five ways to go:
RITUXIMAB — CD20’s last RITE.
OBI — the OBITUARY, same target, deadlier bite.
INE-B — INEVITABLE, NINETEEN swept clean.
BELI — BELLY-empty, no BLyS to feed the machine.
CAR-T — your own cells, reprogrammed and mean.”
Rituximab (-ximab → chimeric mAb)
Target: CD20 on B cells
Mnemonic: RITUXIMAB = CD20’s last RITE. A ritualistic elimination of B cells bearing CD20.
Type: Type I anti-CD20 (chimeric IgG1). Kills via CDC and ADCC.
Key uses: RA (after TNF failure), ANCA vasculitis (GPA/MPA), pemphigus vulgaris.
Pearl: Check hepatitis B before starting — risk of reactivation. Monitor immunoglobulin levels with repeated cycles.
Obinutuzumab (-zumab → humanized mAb)
Target: CD20 on B cells (same target, different mechanism)
Mnemonic: OBI writes the OBITUARY — same target, deadlier bite. More potent B-cell killing than rituximab.
Type: Type II anti-CD20 (humanized, glycoengineered IgG1). Enhanced direct cell death + ADCC; less CDC than rituximab.
Key uses: Lupus nephritis (FDA-approved Oct 2025, based on NOBILITY Phase II + REGENCY Phase III trials). Originally approved in CLL/lymphoma.
Pearl: Glycoengineered Fc region makes it more potent at B-cell depletion. The REGENCY Phase III trial showed 46.4% complete renal response on top of MMF + glucocorticoids. Only anti-CD20 mAb to show complete renal response benefit in a Phase III lupus nephritis trial. Administered twice yearly after 4 initial doses in year one.
Inebilizumab (-zumab → humanized mAb)
Target: CD19 on B cells (broader than CD20)
Mnemonic: INE-B = INEVITABLE, NINETEEN swept clean. CD19 is on more B cells than CD20 — plasmablasts and some plasma cells included.
Key uses: NMOSD/neuromyelitis optica (N-MOmentum trial — FDA approved). IgG4-related disease (FDA-approved Apr 2025, MITIGATE trial — first and only approved treatment for IgG4-RD).
Pearl: CD19 is expressed earlier and later in B-cell development than CD20, so inebilizumab catches cells that rituximab misses — including antibody-secreting plasmablasts. The MITIGATE trial showed 87% reduction in IgG4-RD flare risk (10% vs 60% flare rate).
Belimumab (-mumab → fully human mAb)
Target: BLyS / BAFF (B-lymphocyte stimulator)
Mnemonic: BELI = BELLY-empty, no BLyS to feed the machine. Starves B cells instead of directly killing them.
Key uses: SLE (first drug approved specifically for lupus in 50+ years), lupus nephritis (BLISS-LN trial). IV or subcutaneous.
Pearl: Doesn’t deplete B cells directly — blocks the survival signal. Takes months to see full effect. Often combined with standard therapy.
CAR-T Cell Therapy (chimeric antigen receptor T cells)
Target: CD19 (via patient’s own reprogrammed T cells)
Mnemonic: CAR-T = your own cells, reprogrammed and mean. T cells harvested, engineered with a CD19-targeting receptor, and reinfused.
Key uses: Experimental in autoimmune diseases. Mackensen et al. (NEJM 2022) showed deep remission in SLE, myositis, and systemic sclerosis. Active trials in lupus nephritis, ANCA vasculitis, and more.
Pearl: Cytokine release syndrome (CRS) is the major risk. Unlike conventional drugs, this is a one-time living therapy — the reprogrammed T cells persist and hunt B cells. Drug-free remissions reported lasting 1–2+ years.
Other Key Players
Abatacept (Orencia) — T-Cell Co-Stimulation Blocker
Mechanism: CTLA-4-Ig fusion protein. Blocks Signal 2 (the co-stimulatory handshake).
Mnemonic: “ABATE the handshake — T cells won’t awake.”
Dosing: Weight-based IV monthly; or 125mg SC weekly
FDA: RA, JIA, PsA.
Pearl: It’s a -CEPT (receptor fusion protein). DO NOT combine with TNF inhibitors.
Anifrolumab (Saphnelo) — Type I Interferon Blocker
Mechanism: Monoclonal antibody against type I interferon receptor (IFNAR1).
Name cheat: AN-ti-interFRO-n-lu-mab — the target is in the name.
Dosing: 300mg IV every 4 weeks
FDA: Moderate-to-severe SLE (TULIP-1, TULIP-2 trials).
Pearl: Increased risk of herpes zoster (IFN is critical for antiviral defense).
Avacopan (Tavneos) — Complement Inhibitor
Mechanism: Oral C5a receptor antagonist.
Mnemonic: “AVA-copan is the ORAL ADVOCATE — no steroids needed, C5a can’t communicate.”
Dosing: 30mg PO twice daily
FDA: Adjunctive treatment for ANCA vasculitis (GPA and MPA).
Pearl: ORAL medication. ADVOCATE trial: non-inferior to prednisone taper. Steroid-sparing.
⚡ The Garage — JAK Inhibitors (The Electrical Panel)
JAK inhibitors sneak into the electrical panel and cut the wiring — the signaling system that tells everything to turn on.
“TOFA’s a TOTAL blackout, BARI BARS the first two, UPA blocks just one — JAK1, that’s you.”
Tofacitinib (Xeljanz)
Selectivity: JAK1 + JAK3 (> JAK2). TOFA = TOTAL blackout.
Dosing: 5mg PO twice daily (or 11mg XR once daily)
FDA: RA, PsA, UC, JIA, AS.
Pearl: First FDA-approved JAK inhibitor (2012). Boxed warning: increased risk of MACE, VTE, malignancy (ORAL Surveillance trial). Applies to ALL JAKi as a class.
Baricitinib (Olumiant)
Selectivity: JAK1 + JAK2. BARI BARS the first two.
Dosing: 2mg PO once daily
FDA: RA, alopecia areata.
Pearl: “BARI builds a BARRIER — JAK 1 and 2, plus it regrows your HAIR-i.”
Upadacitinib (Rinvoq)
Selectivity: JAK1 selective. UPA = just U — JAK1 only.
Dosing: 15mg PO once daily (RA, PsA, AS); 30–45mg for IBD induction
FDA: RA, PsA, AS, nr-axSpA, GCA, atopic dermatitis, UC, Crohn’s.
Pearl: Most JAK1-selective. Broadest indication list of the JAKi class.
🌡️ The Smart Thermostat — TYK2 Inhibitor
Same garage, gentler touch, different wiring. Deucravacitinib binds allosterically (at the regulatory domain, not the active site) — a fundamentally different mechanism.
Deucravacitinib (Sotyktu)
Mechanism: Selective TYK2 inhibitor. Oral. Allosteric binding.
Mnemonic: “DEUCE hits TYK-TWO — a different circuit, nothing new to review.”
Dosing: 6mg PO once daily
FDA: Plaque psoriasis, PsA (first TYK2 inhibitor for PsA).
Pearls: TYK2 mediates IL-23, IL-12, and type I IFN signaling. Does NOT carry the JAK inhibitor class boxed warning (different binding mechanism). POETYK PsA-1 and PsA-2 trials.
⛺ The Backyard — PDE4 Inhibitor
Picture kids camping in the backyard — tents up, everything calm. cAMP = the CAMP. PDE4 normally breaks down cAMP (tears down the tents). Apremilast blocks PDE4 — the kids keep camping, everything stays calm.
“Block PDE, let cAMP stay — APREMILAST saves the day.”
Apremilast (Otezla)
Mechanism: PDE4 inhibitor. Oral. Raises intracellular cAMP.
Dosing: Titrate over 6 days to 30mg PO twice daily
FDA: PsA, plaque psoriasis, oral ulcers in Behçet’s disease.
Pearls: Oral, no lab monitoring required. Side effects: diarrhea, nausea, weight loss, headache, depression. Less efficacious than biologics but easiest to start. Behçet’s oral ulcers = unique niche indication.
The Whole House at a Glance
- Garden Hose: MABs go straight for the source, CEPTs catch the runoff, INIBs clog the course.
- Front Door (IL-1): ANA blocks ALL IL-ONE at the door. CANA? CAN only block beta, nothing more.
- Thermostat (IL-6): TOCI TOUCHES the SIX receptor — Giant Cell’s protector. CRP goes silent, but infection still burns.
- TV (IL-17): SECU-rity checks IDs at SEVENTEEN — Crohn’s gets cancelled from the screen.
- IL-12/23: USTE blocks the USUAL TWO. GUSEL and RISAN are precise — only twenty-three, that’s their device.
- Kitchen Freezer (TNF): Five drugs on ICE. CERTified PEG-nant friendly. The CEPT can CATCH but can’t CROHN’s.
- B-Cell Death Row: RITUAL sacrifice (rituximab). Starve the survivors (belimumab).
- Abatacept: ABATE the handshake — T cells won’t awake.
- Anifrolumab: AN-ti-interFRO-n — the target is in the name.
- Avacopan: The ORAL ADVOCATE — no steroids needed.
- Garage (JAK): TOFA’s a TOTAL blackout, BARI BARS the first two, UPA blocks just one. Smart thermostat: DEUCE hits TYK-TWO.
- Backyard (PDE4): Block PDE, let cAMP stay — APREMILAST saves the day.